---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-016970"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:51:15.986374+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income

## Summary
- Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.
- Operating loss $6.1M vs $32,000 loss in 2020; R&D and selling expenses increased.
- Net loss attributable to common $15.9M ($0.32 per share) vs net income $1.4M ($0.03) in 2020.
- Cash $2.3M at Dec 31, 2021; Endari added to Florida Medicaid preferred drug list, UAE approval obtained.
- Licensed IRAK4 inhibitor from Kainos for cancer; telehealth partnership with UpScript launched.

## SEC filing metadata
- accession: 0001213900-22-016970
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/0001213900-22-016970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/ea157399-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-016970
- JSON: https://secwatch.observer/filing/0001213900-22-016970.json
- Plain text: https://secwatch.observer/filing/0001213900-22-016970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.